上海天泽云泰生物医药

T-MAXESTATE is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative gene therapies for rare genetic disorders and chronic diseases. The company utilizes its proprietary V-SmarT AAV vector platform to engineer highly efficient viral delivery systems tailored for specific therapeutic needs. Its lead programs, VGB-R04 for Hemophilia B and VGB-R05 for Hemophilia A, have advanced into clinical trials, demonstrating the company's ability to transition from discovery to human studies. T-MAXESTATE maintains integrated capabilities spanning vector design, process development, and large-scale GMP manufacturing to support its robust pipeline. The firm aims to provide one-time curative treatments for patients with high unmet medical needs through advanced viral vector technology.